Bausch Health Companies Inc. Finite-Lived Intangible Asset, Expected Amortization, Year One
Bausch Health Companies Inc. (BHC) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $849.00 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-07-30
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $849.00M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $847.00M.
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $913.00M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $879.00M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2026-06-30 | $849.00M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $847.00M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $913.00M 10-K · filed 2026-02-19 |
| 2025-09-30 | $879.00M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $875.00M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $875.00M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $989.00M 10-K · filed 2025-02-20 |
| 2024-09-30 | $993.00M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $991.00M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $994.00M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $1.08B 10-K · filed 2024-02-22 |
| 2023-09-30 | $1.07B 10-Q · filed 2023-11-02 |
| 2023-06-30 | $884.00M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $907.00M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $1.03B 10-K · filed 2023-02-23 |
| 2022-09-30 | $1.02B 10-Q · filed 2022-11-03 |
| 2022-06-30 | $1.02B 10-Q · filed 2022-08-09 |
| 2022-03-31 | $1.02B 10-Q · filed 2022-05-10 |
| 2021-12-31 | $1.18B 8-K · filed 2022-05-11 |
| 2021-09-30 | $1.17B 10-Q · filed 2021-11-02 |
| 2021-06-30 | $1.18B 10-Q · filed 2021-08-03 |
| 2021-03-31 | $1.19B 10-Q · filed 2021-05-04 |
| 2020-12-31 | $1.39B 8-K · filed 2021-05-04 |
| 2020-09-30 | $1.41B 10-Q · filed 2020-11-03 |
| 2020-06-30 | $1.41B 10-Q · filed 2020-08-06 |
| 2019-12-31 | $1.62B 10-K · filed 2020-02-19 |
| 2018-12-31 | $1.88B 10-K · filed 2019-02-20 |
| 2017-12-31 | $2.92B 8-K · filed 2018-08-10 |
| 2016-12-31 | $2.51B 10-K · filed 2017-03-01 |
| 2015-12-31 | $2.73B 10-K · filed 2016-04-29 |
| 2014-12-31 | $1.38B 10-K · filed 2015-02-25 |
| 2013-12-31 | $1.41B 10-K · filed 2014-02-28 |
| 2012-12-31 | $1.05B 10-K · filed 2013-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |